Arete Wealth Advisors LLC Buys Shares of 11,014 CRISPR Therapeutics AG (NASDAQ:CRSP)

Arete Wealth Advisors LLC bought a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,014 shares of the company’s stock, valued at approximately $498,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CRSP. Pinnacle Holdings LLC bought a new stake in shares of CRISPR Therapeutics during the first quarter worth $48,000. Ancora Advisors LLC increased its position in shares of CRISPR Therapeutics by 83.2% during the first quarter. Ancora Advisors LLC now owns 1,156 shares of the company’s stock worth $141,000 after acquiring an additional 525 shares in the last quarter. Belpointe Asset Management LLC bought a new stake in shares of CRISPR Therapeutics during the fourth quarter worth $50,000. Bank Julius Baer & Co. Ltd Zurich raised its position in CRISPR Therapeutics by 36.1% in the 1st quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,302 shares of the company’s stock valued at $59,000 after buying an additional 345 shares during the last quarter. Finally, Elkhorn Partners Limited Partnership acquired a new stake in CRISPR Therapeutics in the 4th quarter valued at approximately $55,000. 68.20% of the stock is owned by institutional investors and hedge funds.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP opened at $50.58 on Friday. The company has a market cap of $4.02 billion, a P/E ratio of -9.54 and a beta of 1.62. CRISPR Therapeutics AG has a one year low of $38.94 and a one year high of $73.62. The firm’s fifty day moving average price is $52.39 and its two-hundred day moving average price is $53.39.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, August 7th. The company reported ($0.98) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.13) by $1.15. The company had revenue of $70.00 million for the quarter, compared to analyst estimates of $1.80 million. CRISPR Therapeutics had a negative return on equity of 21.85% and a negative net margin of 240.84%. The firm’s quarterly revenue was up 34900.0% compared to the same quarter last year. During the same quarter last year, the company earned ($2.40) earnings per share. As a group, equities research analysts expect that CRISPR Therapeutics AG will post -4.97 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on CRSP shares. Credit Suisse Group lifted their target price on CRISPR Therapeutics from $62.00 to $63.00 and gave the company a “neutral” rating in a research report on Tuesday, August 8th. Needham & Company LLC reissued a “buy” rating and set a $88.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, August 8th. Chardan Capital cut their price target on shares of CRISPR Therapeutics from $123.00 to $110.00 and set a “buy” rating on the stock in a research report on Monday, August 7th. Citigroup raised shares of CRISPR Therapeutics from a “neutral” rating to a “buy” rating and set a $70.00 price target on the stock in a research report on Thursday, August 17th. Finally, StockNews.com assumed coverage on shares of CRISPR Therapeutics in a research report on Thursday, August 17th. They set a “sell” rating on the stock. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $70.94.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.